Suggested remit: To appraise the clinical and cost effectiveness of pembrolizumab within its marketing authorisation for adjuvant treatment of resected non-small-cell lung cancer.
 
Status In progress
Technology type Medicine
Decision Selected
Process STA
ID number 3907

Project Team

Project lead Emily Richards

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
13 April 2022 - 13 May 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
28 January 2022 In progress. DHSC referral received

For further information on our processes and methods, please see our CHTE processes and methods manual